Bridgeway Capital Management’s Gain Therapeutics GANX Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Shares Change % | Capital Flow | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q2 | $54K | Hold |
30,004
| – | – | ﹤0.01% | 1131 |
|
|
2025
Q1 | $57.3K | Hold |
30,004
| – | – | ﹤0.01% | 1113 |
|
|
2024
Q4 | $64.8K | Buy |
+30,004
| New | +$64.8K | ﹤0.01% | 1145 |
|
|
2024
Q3 | – | Sell |
-40,000
| Closed | -$51.2K | – | 1283 |
|
|
2024
Q2 | $51.2K | Buy |
40,000
+10,000
| +33% | +$12.8K | ﹤0.01% | 1217 |
|
|
2024
Q1 | $113K | Sell |
30,000
-16,100
| -35% | -$60.7K | ﹤0.01% | 1196 |
|
|
2023
Q4 | $151K | Hold |
46,100
| – | – | ﹤0.01% | 1185 |
|
|
2023
Q3 | $149K | Hold |
46,100
| – | – | ﹤0.01% | 1149 |
|
|
2023
Q2 | $207K | Sell |
46,100
-13,900
| -23% | -$62.3K | ﹤0.01% | 1129 |
|
|
2023
Q1 | $289K | Hold |
60,000
| – | – | 0.01% | 1016 |
|
|
2022
Q4 | $188K | Buy |
60,000
+20,000
| +50% | +$62.6K | ﹤0.01% | 1099 |
|
|
2022
Q3 | $130K | Hold |
40,000
| – | – | ﹤0.01% | 1225 |
|
|
2022
Q2 | $144K | Hold |
40,000
| – | – | ﹤0.01% | 1158 |
|
|
2022
Q1 | $163K | Sell |
40,000
-10,000
| -20% | -$40.8K | ﹤0.01% | 1202 |
|
|
2021
Q4 | $267K | Hold |
50,000
| – | – | 0.01% | 1121 |
|
|
2021
Q3 | $372K | Hold |
50,000
| – | – | 0.01% | 1118 |
|
|
2021
Q2 | $501K | Buy |
+50,000
| New | +$501K | 0.01% | 1065 |
|